双时间点68Ga-PSMA PET/CT显像对前列腺癌患者良恶性病变的诊断价值
回顾性纳入44例同时行注射后1小时常规与3小时延迟68Ga-PSMA PET/CT的前列腺癌患者,分析正常器官、原发灶、转移灶及良性病变的SUVmax与SUVmean变化;延迟显像中多数恶性病变摄取增高、良性病变摄取降低,有助于鉴别非特异性PSMA摄取。
要点
- 延迟显像(注射后3小时)原发灶与转移灶SUVmax、SUVmean较常规显像升高,良性病变则降低。
- 肝脏、血液、脾脏延迟显像SUVmax与SUVmean呈下降趋势,腮腺、泪腺、下颌下腺呈升高趋势。
- 对PSMA摄取不明确的病灶,可结合延迟显像的摄取变化方向辅助判断良恶性。
核心结论
- 注射后3小时68Ga-PSMA PET/CT延迟显像在多数前列腺癌恶性病变中表现为更高的摄取和更高的靶本比,而良性病变摄取降低,这一观察可帮助临床医生鉴别前列腺癌患者的非特异性PSMA摄取。
研究设计与样本
- 回顾性研究,纳入44例同时接受常规(注射后1小时)与延迟(注射后3小时)68Ga-PSMA PET/CT扫描的前列腺癌患者,所有病变经病理检查及延长随访确认。
关键影像表现/征象
- 延迟显像(注射后3小时)肝脏、血液、脾脏的SUVmax与SUVmean呈下降趋势,腮腺、泪腺、下颌下腺呈升高趋势;原发灶延迟显像SUVmax 25.09 ± 15.11、SUVmean 14.05 ± 8.02,常规显像分别为17.63 ± 9.61、9.77 ± 5.18(P < 0.001);转移灶延迟显像较常规显像SUVmax与SUVmean呈可比性升高;良性病变延迟显像较常规显像SUVmax降低(3.56 ± 1.49 vs 2.93 ± 1.47,P = 0.001)、SUVmean降低(1.99 ± 0.87 vs 1.65 ± 0.87,P = 0.003)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aimed to ascertain the diagnostic efficacy of routine 68Ga-PSMA imaging conducted 1 h post-injection, in conjunction with delayed imaging performed 3 h post-injection, for differentiating between benign and malignant lesions in prostate cancer (PCa) patients.
METHODS: A retrospective assessment was undertaken on 44 prostate cancer patients who had undergone both routine and delayed 68Ga-PSMA PET/CT scans. Variations in SUVmax and SUVmean values in normal organs, primary prostate cancer sites, metastatic sites, and benign lesions were analyzed. Pathological examination and extended follow-ups were used to confirm all lesions.
RESULTS: The study encompassed 44 patients, presenting 35 primary prostate cancer lesions, 44 metastatic lesions, and 30 benign lesions. Delayed imaging (3 h post-injection) demonstrated a decreasing trend in the SUVmax and SUVmean for the liver, blood, and spleen. Conversely, an increasing trend was observed for the parotid, lacrimal, and submandibular glands. For primary lesions, the SUVmax and SUVmean values were 17.63 ± 9.61 and 9.77 ± 5.18 during routine imaging, and 25.09 ± 15.11 and 14.05 ± 8.02 (P < 0.001) during delayed imaging. A comparable increase in SUVmax and SUVmean was seen in the delayed images for metastatic lesions when juxtaposed with routine images. Nevertheless, benign lesions displayed a decrease in SUVmax and SUVmean during delayed imaging when set against routine imaging (SUVmax: 3.56 ± 1.49 vs 2.93 ± 1.47, P = 0.001; SUVmean: 1.99 ± 0.87 vs 1.65 ± 0.87, P = 0.003).
CONCLUSION: Imaging using 68Ga-PSMA PET/CT at 3 h post-injection manifested a higher uptake and target-to-background uptake in most malignant prostate cancer lesions, but a diminished uptake in benign lesions. This observation can assist clinicians in distinguishing non-specific PSMA uptake in prostate cancer patients based on PSMA PET/CT image.
引用
- Xiao L, Su M, Li Y, et al. Diagnostic value of dual-time point 68Ga-PSMA PET/CT image for benign and malignant lesions in patients with prostate cancer. Abdom Radiol (NY). 2024. PMID: 38546825. doi:10.1007/s00261-024-04269-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。